Advertisement
Canada markets closed
  • S&P/TSX

    21,531.07
    -21.28 (-0.10%)
     
  • S&P 500

    5,130.95
    -6.13 (-0.12%)
     
  • DOW

    38,989.83
    -97.55 (-0.25%)
     
  • CAD/USD

    0.7367
    -0.0011 (-0.15%)
     
  • CRUDE OIL

    78.76
    -1.21 (-1.51%)
     
  • Bitcoin CAD

    91,773.02
    +6,226.13 (+7.28%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,123.10
    +27.40 (+1.31%)
     
  • RUSSELL 2000

    2,074.31
    -2.09 (-0.10%)
     
  • 10-Yr Bond

    4.2190
    +0.0390 (+0.93%)
     
  • NASDAQ futures

    18,244.25
    -94.00 (-0.51%)
     
  • VOLATILITY

    13.49
    +0.38 (+2.90%)
     
  • FTSE

    7,640.33
    -42.17 (-0.55%)
     
  • NIKKEI 225

    40,109.23
    +198.41 (+0.50%)
     
  • CAD/EUR

    0.6781
    -0.0021 (-0.31%)
     

Rakovina Therapeutics Inc. Announces Plan to Apply to Extend Warrant Expiry Dates

Rakovina Therapeutics Inc
Rakovina Therapeutics Inc

VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) announces that it may apply to the TSX Venture Exchange (the “TSXV”) to extend the expiry date of 11,414,750 common share purchase warrants (the “Warrants”) issued by the Company. The original term of the Warrants was two years and they currently expire on March 25, 2023. The Company proposes to extend the expiry date by up to 12 months (the “Warrant Extension”). No other terms of the Warrants are to be amended and the exercise price of each Warrant will remain at $0.40. The proposed amendment of the Warrants is subject to TSXV approval. The extension of the Warrants, if any, would only be effective upon TSXV approval and receipt of the requisite confirmation from the holders of the Warrants.

Additional Information

The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com.

Contact:

Rakovina Therapeutics Inc.
David Hyman
Chief Financial Officer
Email: info@rakovinatherapeutics.com

Investor Relations Contact
IR@rakovinatherapeutics.com

Media Contact
MEDIA@rakovinatherapeutics.com